HIV lymphomas frequently carry mutations in the c-myc protein (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

HIV lymphomas frequently carry mutations in the c-myc protein (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A1141 1994. Unique Identifier : AIDSLINE ICDB/94602827
Spangler G; Gaidano G; Hamdy N; Dalla-Favera R; Magrath I; Bhatia K; Pediatric Branch, NCI, Bethesda, MD 20892

Abstract: Non-Hodgkin's lymphomas, particularly high grade B cell lymphomas, are the most frequent malignancies diagnosed in patients infected with HIV. We have previously reported the occurrence of point mutations in the protein coding region of c-myc in approximately 60% of SNCL in non-HIV infected patients. We have now screened the entire coding region of c-myc in thirty HIV lymphomas and assessed the integrity of the c-myc protein. Our results indicate that the c-myc protein is mutated in 50% of the HIV lymphomas and 75% of small non-cleaved HIV lymphomas. Among 14 other histological subtypes tested (3 large cell non-cleaved, 3 Ki-1 positive and 8 immunoblastic lymphomas) only 2 immunoblastic lymphomas carried c-myc mutations. Unlike intronic mutations, coding region mutations were seen in some tumors that lacked a myc/Ig translocation. However, among 19 tumors with a myc/Ig translocation, 9/11 which lacked EBV had a c-myc mutation, whereas only 2 of 8 EBV positive tumors contained a translocation. These mutations, unlike those that occur in the intron, were also seen in tumors with no evidence of c-myc translocation. The implications of these mutations in the genesis of HIV lymphomas will be discussed.

Keywords: Cell Transformation, Neoplastic/GENETICS Chromosome Aberrations Gene Expression Regulation, Neoplastic/PHYSIOLOGY Gene Frequency Human Lymphoma, AIDS-Related/*GENETICS Mutation/*GENETICS Proto-Oncogene Proteins c-myc/*GENETICS ABSTRACT
941230
M94C4330

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .